Ilya A Lipkovich

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
  2. ncbi Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
    Ilya Lipkovich
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
    Psychopharmacol Bull 42:23-39. 2009
  3. ncbi Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 25:381-6. 2005
  4. doi Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations
    Ilya Lipkovich
    Eli Lilly and Company, Indianapolis, IN, USA
    Stat Med 30:2601-21. 2011
  5. doi Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 170:161-7. 2009
  6. pmc Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
    BMC Psychiatry 9:44. 2009
  7. pmc Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
    Ilya Lipkovich
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 8:78. 2008
  8. pmc Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    BMC Psychiatry 8:65. 2008
  9. pmc Evaluating dose response from flexible dose clinical trials
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
    BMC Psychiatry 8:3. 2008
  10. ncbi Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    J Geriatr Psychiatry Neurol 20:107-14. 2007

Detail Information

Publications18

  1. ncbi Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
    ..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...
  2. ncbi Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials
    Ilya Lipkovich
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
    Psychopharmacol Bull 42:23-39. 2009
    ..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient...
  3. ncbi Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 25:381-6. 2005
    ..Techniques used in this analysis may prove to be useful in assessing the relationship between dose change and safety and efficacy measures...
  4. doi Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations
    Ilya Lipkovich
    Eli Lilly and Company, Indianapolis, IN, USA
    Stat Med 30:2601-21. 2011
    ..We evaluate the operating characteristics of the procedure using a simulation study and illustrate the method with a clinical trial example...
  5. doi Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 170:161-7. 2009
    ..Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice...
  6. pmc Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
    BMC Psychiatry 9:44. 2009
    ..This post-hoc analysis evaluates the relationships among cognition, psychopathology, and psychosocial functioning in patients with schizophrenia at baseline and following sustained treatment with antipsychotic drugs...
  7. pmc Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
    Ilya Lipkovich
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 8:78. 2008
    ..We therefore conducted a post-hoc analysis of clinical trial data, examining early weight gain as a predictor of later substantial weight gain...
  8. pmc Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    BMC Psychiatry 8:65. 2008
    ..The objective of this exploratory analysis was to characterize response in bipolar disorder by identifying groups of patients with similar manic symptom response profiles...
  9. pmc Evaluating dose response from flexible dose clinical trials
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
    BMC Psychiatry 8:3. 2008
    ..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related...
  10. ncbi Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    J Geriatr Psychiatry Neurol 20:107-14. 2007
    ..001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2...
  11. ncbi Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy
    I Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    J Psychiatr Res 41:305-10. 2007
    ..To evaluate the relationship of dose decrease, symptom worsening, and baseline covariates on subsequent relapse during olanzapine treatment in patients with schizophrenia or schizoaffective disorder...
  12. ncbi Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium
    John P Houston
    Lilly Corporate Center, Lilly Research Laboratories, Drop Code 4133, Indianapolis, IN 46285, United States
    J Psychiatr Res 41:616-21. 2007
    ....
  13. doi Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach
    Yongming Qu
    Eli Lilly and Company, Indianapolis, IN 46285, U S A
    Stat Med 28:1402-14. 2009
    ..Simulation shows that all adjusted estimators are much less biased than the naive estimator. Under certain conditions MIMP provides benefits (smaller bias and mean-squared error) compared with existing alternatives...
  14. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
    ..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions...
  15. ncbi A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:157-62. 2006
    ..The objective of this study is to compare olanzapine with ziprasidone therapy in patients with schizophrenia or schizoaffective disorder and experiencing depressive symptoms...
  16. ncbi Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials
    Joseph L Micca
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 14:62-70. 2006
    ..The objective of this study was to evaluate the association of established risk factors for treatment-emergent diabetes (TED) among patients over 65 years of age with dementia who received treatment with olanzapine...
  17. pmc Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm
    Dana S Hardin
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Diabetes Sci Technol 7:420-30. 2013
    ..This research assessed heterogeneity and differential treatment response using the subgroup identification based on differential effect search (SIDES) algorithm with data from a large multinational study...
  18. doi Comparison of several imputation methods for missing baseline data in propensity scores analysis of binary outcome
    Brenda J Crowe
    Eli Lilly and Company, Indianapolis, IN, USA
    Pharm Stat 9:269-79. 2010
    ..Treatment Mean Imputation performed better than MI methods that did not include both the treatment and outcome in the imputer's model...